{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T18:54:00Z","timestamp":1793904840574,"version":"4.8.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patient-derived organoids (PDOs) are valuable in predicting response to cancer therapy. PDOs are ideal models for precision oncologists. However, their practical application in guiding timely clinical decisions remains challenging. This study focused on patients with advanced EGFR-mutated non-small cell lung cancer and employed a cancer organoid-based diagnosis reactivity prediction (CODRP)-based precision oncology platform to assess the efficacy of EGFR inhibitor treatments. CODRP was employed to evaluate EGFR-tyrosine kinase inhibitors (TKI) drug sensitivity. The results were compared to those obtained using area under the curve index. This study validated this index by testing lung cancer-derived organoids in 14 patients with lung cancer. The CODRP index-based drug sensitivity test reliably classified patient responses to EGFR-TKI treatment within a clinically suitable 10-day timeline, which aligned with clinical drug treatment responses. This approach is promising for predicting and analyzing the efficacy of anticancer, ultimately contributing to the development of a precision medicine platform.<\/jats:p>","DOI":"10.1038\/s41698-024-00609-7","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T19:01:47Z","timestamp":1716318107000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Prediction of TKI response in EGFR-mutant lung cancer patients-derived organoids using malignant pleural effusion"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9682-1473","authenticated-orcid":false,"given":"Sang-Hyun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyuhwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunyoung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8557-0992","authenticated-orcid":false,"given":"Kyungmin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyeong Hwan","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1989-1576","authenticated-orcid":false,"given":"Hansom","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yelim","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soeun","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Youl","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongki","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Hyuck","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Jun","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok Whan","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi Hyoung","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwanyong","family":"Hyun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3140-3681","authenticated-orcid":false,"given":"Tae-Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeoun Eun","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6298-2204","authenticated-orcid":false,"given":"Joon Young","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan Kwon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Dong","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Jung","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8572-2595","authenticated-orcid":false,"given":"You-Seok","family":"Hyun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai-Gyu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bosung","family":"Ku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Uk","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4836-8958","authenticated-orcid":false,"given":"Seung Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,21]]},"reference":[{"key":"609_CR1","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603\u2013607 (2012).","journal-title":"Nature"},{"key":"609_CR2","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1126\/science.aao2774","volume":"359","author":"G Vlachogiannis","year":"2018","unstructured":"Vlachogiannis, G. et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science 359, 920\u2013926 (2018).","journal-title":"Science"},{"key":"609_CR3","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cell.2016.06.017","volume":"166","author":"F Iorio","year":"2016","unstructured":"Iorio, F. et al. A Landscape of Pharmacogenomic Interactions in Cancer. Cell 166, 740\u2013754 (2016).","journal-title":"Cell"},{"key":"609_CR4","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1158\/0008-5472.CAN-03-3383","volume":"64","author":"WD Stein","year":"2004","unstructured":"Stein, W. D., Litman, T., Fojo, T. & Bates, S. E. A Serial Analysis of Gene Expression (SAGE) database analysis of chemosensitivity: comparing solid tumors with cell lines and comparing solid tumors from different tissue origins. Cancer Res. 64, 2805\u20132816 (2004).","journal-title":"Cancer Res."},{"key":"609_CR5","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.cell.2016.08.041","volume":"167","author":"A Bruna","year":"2016","unstructured":"Bruna, A. et al. A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. Cell 167, 260\u2013274 e222 (2016).","journal-title":"Cell"},{"key":"609_CR6","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/nm.3954","volume":"21","author":"H Gao","year":"2015","unstructured":"Gao, H. et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat. Med. 21, 1318\u20131325 (2015).","journal-title":"Nat. Med."},{"key":"609_CR7","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1158\/2159-8290.CD-18-0349","volume":"8","author":"H Tiriac","year":"2018","unstructured":"Tiriac, H. et al. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discov. 8, 1112\u20131129 (2018).","journal-title":"Cancer Discov."},{"key":"609_CR8","doi-asserted-by":"publisher","first-page":"122087","DOI":"10.1016\/j.biomaterials.2023.122087","volume":"296","author":"HR Jun","year":"2023","unstructured":"Jun, H. R. et al. High-throughput organo-on-pillar (high-TOP) array system for three-dimensional ex vivo drug testing. Biomaterials 296, 122087 (2023).","journal-title":"Biomaterials"},{"key":"609_CR9","doi-asserted-by":"publisher","unstructured":"Jeong, M. H. et al. An Automated High-Throughput Screening (HTS) Spotter for 3D Tumor Spheroid Formation. Int. J. Mol. Sci. 24, https:\/\/doi.org\/10.3390\/ijms24021006 (2023).","DOI":"10.3390\/ijms24021006"},{"key":"609_CR10","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/s42003-021-02417-2","volume":"4","author":"S Gopal","year":"2021","unstructured":"Gopal, S. et al. 3D tumor spheroid microarray for high-throughput, high-content natural killer cell-mediated cytotoxicity. Commun. Biol. 4, 893 (2021).","journal-title":"Commun. Biol."},{"key":"609_CR11","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/978-1-4939-0882-0_16","volume":"1169","author":"M Rapp","year":"2014","unstructured":"Rapp, M., Anz, D. & Schnurr, M. Isolation of intratumoral leukocytes of TLR-stimulated tumor-bearing mice. Methods Mol. Biol. 1169, 175\u2013179 (2014).","journal-title":"Methods Mol. Biol."},{"key":"609_CR12","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.21037\/tlcr-22-79","volume":"11","author":"HA Jung","year":"2022","unstructured":"Jung, H. A. et al. Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22. Transl. Lung Cancer Res. 11, 1369\u20131379 (2022).","journal-title":"Transl. Lung Cancer Res."},{"key":"609_CR13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria, J. C. et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N. Engl. J. Med. 378, 113\u2013125 (2018).","journal-title":"N. Engl. J. Med."},{"key":"609_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"609_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-989","volume":"14","author":"AC Toffart","year":"2014","unstructured":"Toffart, A. C. et al. Evaluation of RECIST in chemotherapy-treated lung cancer: the Pharmacogenoscan Study. BMC Cancer 14, 989 (2014).","journal-title":"BMC Cancer"},{"key":"609_CR16","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1097\/MCP.0b013e3283615b67","volume":"19","author":"HE Davies","year":"2013","unstructured":"Davies, H. E. & Lee, Y. C. Management of malignant pleural effusions: questions that need answers. Curr. Opin. Pulm. Med. 19, 374\u2013379 (2013).","journal-title":"Curr. Opin. Pulm. Med."},{"key":"609_CR17","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1164\/rccm.201807-1415ST","volume":"198","author":"DJ Feller-Kopman","year":"2018","unstructured":"Feller-Kopman, D. J. et al. Management of Malignant Pleural Effusions. An Official ATS\/STS\/STR Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 198, 839\u2013849 (2018).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"609_CR18","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/resp.12496","volume":"20","author":"JM Porcel","year":"2015","unstructured":"Porcel, J. M. et al. Clinical features and survival of lung cancer patients with pleural effusions. Respirology 20, 654\u2013659 (2015).","journal-title":"Respirology"},{"key":"609_CR19","doi-asserted-by":"publisher","first-page":"ii32","DOI":"10.1136\/thx.2010.136994","volume":"65","author":"ME Roberts","year":"2010","unstructured":"Roberts, M. E. et al. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax 65, ii32\u2013ii40 (2010).","journal-title":"Thorax"},{"key":"609_CR20","doi-asserted-by":"publisher","first-page":"160","DOI":"10.4103\/0970-2113.201305","volume":"34","author":"R Dixit","year":"2017","unstructured":"Dixit, R. et al. Diagnosis and management options in malignant pleural effusions. Lung India 34, 160\u2013166 (2017).","journal-title":"Lung India"},{"key":"609_CR21","doi-asserted-by":"publisher","first-page":"107588","DOI":"10.1016\/j.celrep.2020.107588","volume":"31","author":"KK Dijkstra","year":"2020","unstructured":"Dijkstra, K. K. et al. Challenges in Establishing Pure Lung Cancer Organoids Limit Their Utility for Personalized Medicine. Cell Rep. 31, 107588 (2020).","journal-title":"Cell Rep."},{"key":"609_CR22","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.stem.2022.04.006","volume":"29","author":"S Ding","year":"2022","unstructured":"Ding, S. et al. Patient-derived micro-organospheres enable clinical precision oncology. Cell Stem Cell 29, 905\u2013917.e906 (2022).","journal-title":"Cell Stem Cell"},{"key":"609_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22676-1","volume":"12","author":"Y Hu","year":"2021","unstructured":"Hu, Y. et al. Lung cancer organoids analyzed on microwell arrays predict drug responses of patients within a week. Nat. Commun. 12, 2581 (2021).","journal-title":"Nat. Commun."},{"key":"609_CR24","doi-asserted-by":"publisher","first-page":"100911","DOI":"10.1016\/j.xcrm.2022.100911","volume":"4","author":"HM Wang","year":"2023","unstructured":"Wang, H. M. et al. Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study. Cell Rep. Med. 4, 100911 (2023).","journal-title":"Cell Rep. Med."},{"key":"609_CR25","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s40262-014-0137-2","volume":"53","author":"H Yu","year":"2014","unstructured":"Yu, H. et al. Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets. Clin. Pharmacokinet. 53, 305\u2013325 (2014).","journal-title":"Clin. Pharmacokinet."},{"key":"609_CR26","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nrclinonc.2009.62","volume":"6","author":"H Linardou","year":"2009","unstructured":"Linardou, H., Dahabreh, I. J., Bafaloukos, D., Kosmidis, P. & Murray, S. Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat. Rev. Clin. Oncol. 6, 352\u2013366 (2009).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"609_CR27","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1001\/jamaoncol.2016.0639","volume":"2","author":"AG Sacher","year":"2016","unstructured":"Sacher, A. G. & Gandhi, L. Biomarkers for the Clinical Use of PD-1\/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review. JAMA Oncol. 2, 1217\u20131222 (2016).","journal-title":"JAMA Oncol."},{"key":"609_CR28","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.ccell.2018.03.005","volume":"33","author":"R Zappasodi","year":"2018","unstructured":"Zappasodi, R., Merghoub, T. & Wolchok, J. D. Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. Cancer Cell 33, 581\u2013598 (2018).","journal-title":"Cancer Cell"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-024-00609-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-024-00609-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-024-00609-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T19:06:51Z","timestamp":1716318411000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-024-00609-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,21]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["609"],"URL":"https:\/\/doi.org\/10.1038\/s41698-024-00609-7","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,21]]},"assertion":[{"value":"8 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"111"}}